Background-Previous studies using quantitative coronary angiography have demonstrated that statin therapy slows the progression of coronary stenoses in proportion to average low-density lipoprotein cholesterol levels during therapy. However, no major statin monotherapy study has demonstrated either halted progression or regression of angiographic disease. A Study to Evaluate the Effect of Rosuvastatin on Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID) assessed whether rosuvastatin could regress coronary atherosclerosis by intravascular ultrasound and quantitative coronary angiography. Intravascular ultrasound showed atheroma volume regression in a single coronary artery with Ͻ50% angiographic luminal narrowing. Methods and Results-ASTEROID treated 507 coronary disease patients with rosuvastatin 40 mg/d for 24 months.
increases in percent diameter stenosis and decreases in minimum lumen diameter (MLD). The ability of statins to reduce the progression of atherosclerotic lesions or to result in the regression of atherosclerotic lesions has been evaluated in several previous studies. [1] [2] [3] [4] [5] [6] These studies reported smaller increases in percent diameter stenosis and/or smaller decreases in coronary MLD, as assessed by QCA, in patients treated with fluvastatin, pravastatin, lovastatin, or simvastatin compared with those treated with placebo. Fewer patients treated with a statin developed new lesions compared with patients treated with placebo, 2, 3, 5, 6 and statin-treated patients were more likely to have categorical regression and less likely to have categorical progression than placebo-treated patients. [1] [2] [3] [4] [5] [6] However, no major statin monotherapy study has achieved either a halting of progression or regression of angiographic disease.
QCA has important limitations. Only the lumen, not the vessel wall itself, is visualized with angiography. The extent of atheroma within the vessel wall is not reliably ascertained by standard angiographic techniques, 7 and there may be extensive atheromatous involvement with only minimal impingement on the lumen. Furthermore, lumen size is a relatively crude measure of atherosclerotic disease, especially in patients with only mildly stenotic lesions. It has been known for 20 years that there is a compensatory adaptive enlargement or "remodeling" of atherosclerotic human coronary arteries with preservation of the cross-sectional area of the lumen in the early stages of the disease process. This knowledge is based on the findings of autopsy studies that demonstrated that the coronary lumen did not decrease in size until the atheroma occupied Ͼ40% of the area encompassed by the outside wall of the artery. 8 IVUS provides images of the wall as well as the lumen, allowing accurate assessment of atheroma volume, but it is limited to larger, proximal segments with a smaller range of stenosis that will safely accommodate the relatively largebore IVUS catheter. As such, prospective IVUS studies focus on the examination of the low end of the spectrum of diseased coronary arteries in regard to luminal narrowing or obstruction. QCA, by providing lumen information throughout the coronary tree, including more diseased segments, branch vessels, and distal stenoses, complements the detailed imaging data provided by IVUS for larger vessels. ASTEROID was designed to assess the effects of 2 years of therapy with 40 mg/d rosuvastatin on coronary atherosclerosis measured with both IVUS and QCA. The IVUS assessment of 1 major coronary artery in each patient, which was the primary objective of ASTEROID, has been previously reported. 9 Here, we broaden the assessment of the ASTEROID patients, reporting on the effects of rosuvastatin on discrete coronary stenoses by QCA, which was a secondary end point of the study.
Methods

Patients and Treatment
ASTEROID (4522IL/0076) was a prospective, multicenter, international open-label trial. 9 The institutional review board or ethics committee of all participating centers approved the protocol, and all patients provided written informed consent. This study included men and women Ն18 years of age with a clinical indication for coronary catheterization and angiographic evidence of CAD who met specific angiographic and IVUS criteria. Use of lipid-lowering medication for Ͼ3 months within the previous 12 months was not allowed. Patients who received lipid-lowering therapy in the 4 weeks before enrollment had a 4-week washout period to obtain accurate baseline lipid values. Any baseline level of low-density lipoprotein cholesterol (LDL-C) was permitted; however, patients with uncontrolled triglyceride levels (Ն500 mg/dL [5.7 mmol/L]) or poorly controlled diabetes (glycosylated hemoglobin levels Ն10%) were excluded. Inclusion required demonstration of at least 1 stenosis of Ͼ20% angiographic luminal diameter narrowing by visual estimation in any coronary vessel. The left main coronary artery had to have Յ50% reduction in lumen diameter, and the target vessel for IVUS interrogation could not have undergone angioplasty or bypass surgery or have Ͼ50% luminal narrowing throughout a target segment with a minimum length of 40 mm. Similarly, segments for QCA analyses could not have undergone bypass surgery or percutaneous coronary intervention. Patients were treated with rosuvastatin 40 mg/d for 24 months. They then underwent a second angiography and IVUS measurement.
Quantitative Coronary Angiography
Measurement of change in percent diameter stenosis for all stenoses Ͼ25% at baseline was defined as a prespecified outcome variable for ASTEROID. This is similar to the baseline stenoses examined in other QCA studies such as the Canadian Coronary Atherosclerosis Intervention Trial 2 and the Lipoprotein and Coronary Atherosclerosis Study. 6 For consistency with the prespecified percent diameter stenosis analysis, we also examined MLD in the same segments with Ͼ25% stenosis at baseline. Centers performed coronary angiography as part of the entry criteria for patients to be enrolled in the study, and follow-up angiography was performed at the end of the study. After administration of intracoronary nitroglycerin (100 to 300 g), standard angiographic images were obtained so that each coronary segment was recorded in at least 2 orthogonal views. Images were recorded either on a DICOM-formatted CD (Ͼ99% of studies) or on cine film. Cine film images were subsequently digitized for analysis. Ten segments of the coronary arteries and their major branches were analyzed using end-diastolic frames with the Cardiovascular Angiography Analysis System-II (CAAS-II, Pie Medical Imaging BV, Maastricht, the Netherlands) applying an automated edge detection algorithm. 10 The Angiography Core Laboratory at the Cleveland Clinic made all measurements. Each measurement was made by 2 technicians and reviewed by the medical director. All measurements were performed at the end of the study, after both baseline and follow-up examinations were available. Baseline and follow-up recordings were resequenced using random assignments, and the paired baseline and follow-up images were analyzed by personnel blinded to the sequences.
The reference diameter and most narrow point (ie, the MLD) were defined in each segment. Percent stenosis was defined as follows: [(reference diameterϪMLD)/reference diameter]ϫ100. The average of all lesions with Ͼ25% and Ͻ100% stenosis at baseline that also had posttreatment measurements in the corresponding segments was calculated for each patient. From these values, the change from baseline was calculated for each patient.
The diameter of the catheter tip was measured with digital calipers and used for image calibration. The MLD values for each patient at baseline for all segments in which the reference vessel size was Ն1 mm and the percent stenosis was Ͼ25% were calculated. The MLD on treatment was then calculated for the matching segments. The average change in MLD from baseline was calculated for each patient using these values. Clinically relevant regression or progression was defined as a nominal change (from baseline to 2 years) of Ն10% for percent diameter stenosis 11 and Ն0.2 mm (prespecified) for MLD.
The quality assurance process in the Angiography Core Laboratory was as follows. Images from 6 randomly selected patients were provided quarterly to each reviewer for measurement. The mean and SD across reviewers were determined, and the coefficient of variation (coefficient of variationϭ[SD/mean]ϫ100) was calculated to assess the degree of interreviewer variability. The set limit for the coefficient of variation was 15%. This analysis was performed on a quarterly basis in the Angiography Core Laboratory on randomly selected images from multiple trials. These data have been reported previously, with intraobserver correlations for reference diameter and MLD of 0.996 and 0.997, respectively. 12 For these data, the mean differences between measurements for MLD and percent diameter stenosis were 0.0195 mm (SD, 0.22) and 1.42% (SD, 8.25), respectively. Quarterly reviews of quality assurance data by the study physician and statistician did not identify any notable inconsistencies in the QCA data used in the ASTEROID analyses.
Statistical Analysis
Regression of CAD was evaluated for the analysis set for the 2 QCA end points-percent diameter stenosis and MLD-for all lesions with Ͼ25% stenosis at baseline. Results are presented in terms of mean and median change from baseline, along with associated SD or 25th and 75th percentile values. Because the assumption of normal-ity was not met for the data in these analyses, the change from baseline was tested with the Wilcoxon signed-rank test. The proportion of patients categorized as regressors versus progressors was tested using a 2-sided binomial test. ANOVA (including a factor for geographic region) was used to analyze the percent change from baseline in time-weighted average on-therapy values for lipids and lipoproteins. Least-squares linear regression analysis was applied to the mean QCA results for multiple trials, weighted by the number of patients in each arm, similar to that performed previously. 13 The authors had full access to and take full responsibility for the integrity of the data. All authors have read and agree to the manuscript as written.
Results
Of the 507 patients enrolled in ASTEROID, 379 (75%) had baseline and follow-up angiograms. Of these 379 patients, 292 (77%) had Ն1 segment with Ͼ25% diameter stenosis at baseline that were matched with angiograms at the end of the study, permitting measurement of the change in the severity of stenosis ( Figure 1 ). A total of 613 coronary segments in the 292 patients (median, 2 segments per patient) met the criterion of Ͼ25% stenosis at baseline and had stenosis measurements at both baseline and the end of the study. Of these patients, 11 had valid stenosis measurements but lacked calibrated MLD measurements at either baseline or the end of the study; thus, MLD analyses are based on 586 segments from 281 patients.
Patient demographics for the enrolled population are presented in Table 1 for both those with stenoses analyzed in this study and those who were not included in the analysis. The baseline demographics were very similar for both groups. For the QCA group, most patients were male and overweight, and the average age was 59 years. Almost all patients were hypertensive and white; 27% had a previous myocardial infarction; and 13% were diabetic. The baseline and on-treatment lipid data shown in Table 2 are similar to the results for the full ASTEROID intentionto-treat group reported previously. 9 Rosuvastatin treatment resulted in a 53.3% reduction in LDL-C, producing a mean of 61.1 mg/dL. High-density lipoprotein cholesterol (HDL-C) increased by 13.8% to a mean of 48.3 mg/dL. The ratio of LDL-C to HDL-C decreased by 58.2% to 1.33.
The baseline percent diameter stenosis and MLD and the changes with 24 months of rosuvastatin treatment are summarized in Table 3 . MeanϮSD percent diameter stenosis decreased from 37.3Ϯ8.4% (median, 35.7%; range, 26% to 73%) to 36.0Ϯ10.1% (median, 34.5%; range, 8% to 74%; PϽ0.001). MeanϮSD MLD increased from 1.65Ϯ0.36 mm (median, 1.62 mm; range, 0.56 to 2.65 mm) to 1.68Ϯ0.38 mm (median, 1.67 mm; range, 0.76 to 2.77 mm; PϽ0.001).
Most patients showed a reduction in the percent diameter stenosis (regression), as shown in Table 4 . By the clinical definition of regression or progression for percent diameter stenosis (Ն10% change from baseline), 22 patients (7.5%) showed regression. Changes of Ͻ10% were seen in 261 patients (89.4%), and 9 patients (3.1%) showed progression.
Most patients showed a measurable increase in MLD (regression; Table 4 ). By the prespecified definition of clinical regression or progression (change of Ն0.2 mm in MLD from baseline to follow-up), 34 patients (12.1%) showed regression. Changes of Ͻ0.2 mm were seen in 230 patients (81.9%), and 17 patients (6.0%) showed progression.
There were no significant correlations between the ontherapy lipid levels and changes in the QCA parameters. There was, however, a trend toward an effect of the modification of the lipid profile if one examined the extremes of the lipid responses. For on-therapy LDL-C and on-therapy HDL-C, the highest quartile of lipid responses was, on average, associated with more beneficial effects on percent diameter stenosis and MLD than the lowest quartile of those lipid responses.
The safety profile of the study has been reported previously. 9 Among the 507 patients who received drug therapy in ASTEROID, there were 4 deaths (0.8%). Myocardial infarctions occurred in 10 patients (2.0%), 5 of whom had QCA analysis. Strokes occurred in 3 patients (0.6%), 2 of whom had QCA analysis.
Discussion
QCA and IVUS are 2 methods to quantify changes in the coronary arteries over time, and both have been used in clinical trials as surrogate measures to examine the effects of therapies on the progression of CAD. This analysis from ASTEROID examined the effects of intensive statin therapy on the lumen of the coronary artery measured as percent diameter stenosis and MLD assessed by QCA in lesions causing Ͼ25% and Ͻ100% stenosis in any major coronary segment at baseline. In the primary ASTEROID results previously reported, 9 IVUS was used to measure the change in percent atheroma volume, change in atheroma volume in the 10-mm subsegment with the greatest disease severity at baseline (both primary efficacy parameters), and change in normalized total atheroma volume for the entire artery (secondary efficacy parameter) in a single coronary artery that was angiographically normal or had Ͻ50% stenosis at baseline. IVUS showed regression of all 3 measures of atheroma volume in the examined coronary arteries. In this analysis, intensive statin therapy led to a significant change in the coronary artery lumen in areas with luminal narrowing at baseline, with a reduction in percent diameter stenosis, a prespecified analysis, and an improvement in MLD in the same segments. The mean percent diameter stenosis was reduced by 1.3% (median change, 0.5%) during the study, and the mean MLD increased by 0.03 mm (median, 0.02 mm). These changes were in the same direction as and complement the IVUS findings of a decrease in percent atheroma volume (mean, 0.98%; median, 0.79%), reduction in atheroma volume of the most diseased segment (mean, 6.1 mm 3 ; median, 5.6 mm 3 ), and reduction in total atheroma volume (mean, 14.7 mm 3 ; median, 12.5 mm 3 ) that were previously reported. 9 In the present trial, we show that 2 imaging modalities, which clearly measure different parameters and focus on different segments of the coronary arteries, demonstrated concordant improvements in angiographic measurements of lumen dimension and IVUS measurements of atheroma volume consistent with regression of atherosclerosis with intensive statin therapy in ASTEROID. Whereas IVUS focuses on the portion of the coronary tree with the least luminal narrowing, QCA focuses on the portion with the greatest luminal narrowing. A previous trial showed that changes in lumen dimension over time correlated weakly with IVUS parameters but that patients with angiographic progression over time had greater increases in plaque volume over time. 14 Another study found no correlation between IVUS and QCA parameters. 12 QCA measures the lumen and therefore focuses on lesions that narrow the lumen, and progression of CAD as measured by QCA has been shown to predict clinical cardiovascular events such as nonfatal myocardial infarction, CAD mortality, and the need for revascularization in the Program for the Surgical Control of the Hyperlipidemias, 15 the Montreal Heart Institute study of nicardipine, 16 and the Cholesterol Lowering Atherosclerosis Study. 17 The change in MLD was the only measure to be independently associated with risk of coronary events in the Cholesterol Lowering Atherosclerosis Study. 17 Larger changes in the progression of CAD measured by QCA may reflect plaque instability and thrombosis, which led to luminal narrowing, that is, silent atherothrombotic events. The clinical significance of regression of CAD as measured by QCA has not been well studied; although previous QCA trials with statins consistently showed fewer patients with progression and more patients with regression than placebo, on average, patients continued to have progression of atherosclerosis in all the multicenter trials with statin monotherapy. 13 Perhaps the most important finding in this trial is that aggressive lipid-modifying therapy arrested progression or stabilized coronary stenoses during the 2 years of the study, as evidenced by the fact that 97% of patients remained stable or had regression in terms of percent diameter stenosis and that 94% of patients remained stable or had regression in terms of MLD (Table 4 ). Plaque stabilization may be more important than gross anatomic changes as a mechanism for the clinical benefits of statin therapy on CAD event reduction observed in clinical trials. 18 One of the key clinical questions in the treatment of atherosclerotic CAD is the determination of clinical targets to optimize therapy. Although the National Cholesterol Education Program Adult Treatment Panel III guidelines focus on achieving a target LDL-C level, 19 others have argued that achieving a large percent reduction in LDL-C with intensive statin therapy may be a valid alternative approach, 20 and the recent American Heart Association/American College of Cardiology secondary prevention guidelines suggest that it is reasonable to achieve an LDL-C goal of Ͻ70 mg/dL or a reduction in LDL-C of Ͼ50%. 21 We performed an analysis, weighted by sample size, of multicenter angiographic trials with statins to explore the relationship between angiographic changes and LDL-C levels achieved or percent reduction in LDL-C achieved. As shown in Figure 2A and 2B, the change in percent diameter stenosis had a similar association with either LDL-C level achieved or the percent reduction in LDL-C. The change in MLD also was similarly associated MLD smaller by Ն0.2 mm (progression*) 17 6.0 *Indicates that the proportion of regressors was significantly greater than the proportion of progressors, all PϽ0.03.
†Progression and regression predefined as absolute changes Ն0.2 mm in MLD.
with both LDL-C level achieved and the percent reduction in LDL-C as shown in Figure 2C and 2D.
Statins have other effects on lipids and lipoproteins besides reducing LDL-C, including lowering triglycerides and apolipoprotein B and raising HDL-C. The change in percent diameter stenosis had similar associations with on-treatment HDL-C level or percent change in HDL-C ( Figure 3A and  3B) , whereas the change in MLD had a closer association with percent change in HDL-C than on-treatment HDL-C level. Interestingly, a previously published analysis, which combined raw data from 4 IVUS trials in which 1455 patients had serial IVUS examinations on statin therapy, found that patients who achieved an LDL-C level of Ͻ87.5 mg/dL and had an increase in HDL-C of Ͼ7.5% had, on average, regression of atherosclerosis as measured by percent atheroma volume or total atheroma volume. 22 Although ASTER-OID was 1 of the 4 studies in this analysis of IVUS data, the other 3 trials that made up the IVUS assessment were not a part of the QCA analyses in Figures 2 and 3 . The hypothesis that the beneficial effects of statins on coronary atherosclerosis are related to reductions in LDL-C and increases in HDL-C, which is supported by these retrospective analyses of both angiographic and IVUS trials, is being prospectively tested in the Study of Coronary Atheroma by Intravascular Ultrasound: Effect of Rosuvastatin Versus Atorvastatin, which will compare high doses of 2 statins, atorvastatin 80 mg and rosuvastatin 40 mg, which differ in the LDL-C reductions and HDL-C increases they provide.
Limitations of the present study include the absence of a control group. However, it was considered unethical to treat patients with advanced CAD with placebo or a less effective statin. We compensated for the lack of a control group by blinding date information on the angiograms and resequencing them using random assignments to eliminate observer with mechanisms other than inhibition of HMG-CoA reductase that had marked benefits on both LDL-C and HDL-C levels but did not lead to improved outcomes on either coronary atherosclerosis or clinical events. 24, 25 An additional limitation is that neither QCA nor IVUS as used in ASTEROID provides any information on the impact of statins or lipid changes on plaque composition, which, at least theoretically, may correlate more closely with event reduction. Of interest will be future studies that focus on how therapies both affect anatomic parameters and modify plaque composition, which may beneficially affect the vulnerability of patients to future clinical events.
Conclusions
Rosuvastatin treatment for 24 months resulted in mean LDL-C levels well below 70 mg/dL accompanied by significant increases in HDL-C and produced regression by decreasing percent arterial stenosis and improving MLD as measured by QCA in patients with CAD.
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